TICKERNERD
Menu
COYACOYAHealthcare · Biotechnology

COYA Stock Forecast: Coya Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$4.99
+1.63% on the day

The 7 Wall Street analysts covering Coya Therapeutics, Inc. hold a median 12-month price target of $16 — +210.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$115.2M
Ticker Nerd rank
64 / 100
Median analyst target
$16
Analysts covering
7
Revenue$244K+49.0% y/y
Operating income−$7.0M
Net income−$6.6M
Free cash flow−$8.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.5%
1M
+8.2%
YTD
−14.0%
1Y
−20.9%
From 52W high
−32.2%
From 52W low
+32.0%
$3.78
$7.36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COYA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Coya Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
91
Size
73
Revisions
72
Volatility
61
Quality
61
Value
52
Accruals
36
Momentum
32
Issuance
32

Growth (91): Sales and profits are climbing, and climbing faster than before.

Issuance (32): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

COYA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COYA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26COYAHigh $18Median $16Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $12Median $16High $18

The green dot is the last close — the median target sits +210.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Sept 2026BTIGReiteratesBuy$16
24 Aug 2026Roth CapitalReiteratesBuy$12
24 Aug 2026Roth CapitalReiteratesBuy—
12 Aug 2026Chardan CapitalMaintainsBuy$14
12 Aug 2026Chardan CapitalMaintainsBuy—
12 June 2026Chardan CapitalMaintainsBuy$14
12 June 2026Chardan CapitalMaintainsBuy—
5 June 2026Roth CapitalInitiatesBuy$12
5 June 2026Roth CapitalInitiatesBuy—
10 Apr 2026D. Boral CapitalMaintainsBuy—
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026D. Boral CapitalMaintainsBuy—
16 Mar 2026Chardan CapitalMaintainsBuy—
16 Mar 2026D. Boral CapitalMaintainsBuy—
18 Feb 2026D. Boral CapitalMaintainsBuy—
2 Feb 2026HC Wainwright & Co.ReiteratesBuy—
21 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026Chardan CapitalMaintainsBuy—
8 Jan 2026D. Boral CapitalMaintainsBuy—
5 Jan 2026D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COYA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

COYA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Coya Therapeutics, Inc. returned −20.9% against +16.2% for the S&P 500, dividends included.

COYA vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26COYAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COYA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Coya Therapeutics, Inc. (COYA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.9×

Cheaper than 89% of US stocks

Price / sales
14.4×

Cheaper than 11% of US stocks

Price / book
2.7×

Cheaper than 35% of US stocks

EV / EBITDA
−3.4×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
49.0%

Higher than 86% of US stocks

Earnings growth (YoY)
49.0%

Higher than 74% of US stocks

Gross margin
—
Operating margin
−2890.5%

Higher than 4% of US stocks

Net margin
−270.2%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−60.5%

Higher than 19% of US stocks

Return on assets
−32.3%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Coya Therapeutics, Inc. (COYA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Coya Therapeutics, Inc. has a market value of $115.2M and an enterprise value of $70.6M.

  • Revenue in the twelve months to 30 June 2026: $8.0M. The latest quarter grew 49.0% year on year.

  • Net income over the same four quarters: −$21.7M, a −270.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$16.6M.

  • Shares outstanding: 23.5M.

  • Trailing P/E: −3.9×; forward P/E: −2.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Coya Therapeutics, Inc. employs 8 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

COYA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
COYACoya Therapeutics, Inc.$115.2M
64
HURATuHURA Biosciences, Inc.$117.2M
18
FHTXFoghorn Therapeutics, Inc.$116.6M
40
TNYATenaya Therapeutics, Inc.$117.8M
32
VTVTvTv Therapeutics, Inc.$118.5M
77
ENGNenGene Therapeutics, Inc.$114.9M
18
HUMAHumacyte, Inc.$120.6M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Coya Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COYA news & analysis

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Business Wire · 5 Oct 2026positive

Coya Therapeutics announced the completion of full enrollment of the planned 120 participants in its Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, its combination of low-dose IL-2 and CTLA-4 Ig, for the potential treatment of amyotrophic lateral sclerosis.

Why it matters — Full enrollment in the pivotal ALSTARS trial moves Coya's lead candidate, COYA 302, a step closer to clinical data for ALS, a key milestone for the company's neurodegenerative disease pipeline.

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Business Wire · 15 Sept 2026positive

Coya Therapeutics announced that the 100th patient has been enrolled in its ongoing Phase 2/3 ALSTARS Trial evaluating COYA 302, its combination of low-dose IL-2 and CTLA-4 Ig, for the treatment of amyotrophic lateral sclerosis. The trial is registered under NCT07161999.

Why it matters — This milestone marks continued progress in the clinical development of Coya's lead candidate COYA 302 for ALS.

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

Business Wire · 8 Sept 2026positive

Coya Therapeutics announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences, part of a Special Issue on GLP-1 receptor agonists in health and disease. The study demonstrated combination immunomodulatory effects of COYA 303 in a well-established model of peripheral and CNS inflammation.

Why it matters — This publication provides independent validation and visibility for COYA 303's preclinical potential in addressing inflammation in the peripheral and central nervous systems, relevant to Coya's therapeutic pipeline.

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Business Wire · 11 Aug 2026positive

Coya Therapeutics reported financial results for the quarter ended June 30, 2026, and provided a corporate update. The company highlighted notable progress advancing its lead program, COYA 302, a biologic intended to enhance Treg function in neurodegenerative disorders.

Why it matters — COYA watchers would care because the company reports on the advancement of COYA 302, its lead clinical program, which is central to its pipeline and future value.

FAQ

Frequently asked questions about COYA stock

What is the COYA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Coya Therapeutics, Inc. have a median 12-month price target of $16, with estimates ranging from $12 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COYA stock a buy right now?

Of the 7 analysts covering Coya Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Coya Therapeutics, Inc. 64 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COYA?

As at 8 Oct 2026, Coya Therapeutics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).

Will COYA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +210.6% from the last close, and Ticker Nerd's factor model ranks Coya Therapeutics, Inc. 64 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COYA stock forecast for 2030?

No analyst covering Coya Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $18 over the next 12 months.

How has COYA stock performed over the past year?

Coya Therapeutics, Inc. returned -20.9% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Coya Therapeutics, Inc. do?

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs.

What is the latest news on COYA?

The most recent item we track (Business Wire, 5 Oct 2026): "Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS". Coya Therapeutics announced the completion of full enrollment of the planned 120 participants in its Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, its combination of low-dose IL-2 and CTLA-4 Ig, for the potential treatment of amyotrophic lateral sclerosis.

Company

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. The company’s current pipeline centers on multiple immune-modulating approaches, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. These programs are designed to address systemic inflammation and neuroinflammation across serious conditions such as neurodegenerative, autoimmune, chronic inflammatory, and metabolic diseases. Coya Therapeutics is particularly active in advancing treatments intended to restore immune balance and support disease-modifying approaches in areas with significant unmet medical need. Based in Houston, Texas, Coya Therapeutics operates within the broader healthcare and biotechnology markets, where its platform-based strategy positions it as a developer of specialized immunotherapy candidates.

CEO Dr. Arun Swaminathan Ph.D. · 8 employees · United States · https://www.coyatherapeutics.com